Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | Blinatumomab and inotuzumab in children with R/R B-ALL

Sarah Tasian • 20 Apr 2021
AACR 2021
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

Sarah K. Tasian, MD, University of Pennsylvania School of Medicine and Abramson Cancer Center, Philadelphia, PA, outlines the use of blinatumomab and inotuzumab for the treatment of children with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The study reported that both blinatumomab and inotuzumab can induce deep remissions in patients with R/R B-ALL and that blinatumomab can be used as an effective bridging therapy during infection. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Sarah K. Tasian, MD, has received research funding from Incyte Corporation, and has participated in scientific advisory boards for Kura Oncology and Aleta Biotherapeutics.

More from Sarah Tasian

The management of Ph-like ALL: moving towards an individualized precision medicine approach
2:00
The management of Ph-like ALL: moving towards an individualized precision medicine approach
Sarah Tasian • 3 Sep 2025
Diagnostic advances that could further individualize care in ALL
0:40
Diagnostic advances that could further individualize care in ALL
Sarah Tasian • 3 Sep 2025
How advances in molecular sequencing technologies have shaped ALL therapy
1:05
How advances in molecular sequencing technologies have shaped ALL therapy
Sarah Tasian • 3 Sep 2025
Precision medicine in pediatric ALL
1:09
Precision medicine in pediatric ALL
Sarah Tasian • 4 Jun 2023

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals